TY - JOUR
T1 - Gene signature of children with severe respiratory syncytial virus infection
AU - Dapat, Clyde
AU - Kumaki, Satoru
AU - Sakurai, Hiroki
AU - Nishimura, Hidekazu
AU - Labayo, Hannah Karen Mina
AU - Okamoto, Michiko
AU - Saito, Mayuko
AU - Oshitani, Hitoshi
N1 - Funding Information:
This study was supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 16K15369 and by the Japan Initiative for Global Research Network on Infectious Diseases of the Japan Agency for Medical Research and Development (AMED) Grant Numbers JP19fm0108013.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/5
Y1 - 2021/5
N2 - Background: The limited treatment options for children with severe respiratory syncytial virus (RSV) infection highlights the need for a comprehensive understanding of the host cellular response during infection. We aimed to identify host genes that are associated with severe RSV disease and to identify drugs that can be repurposed for the treatment of severe RSV infection. Methods: We examined clinical data and blood samples from 37 hospitalized children (29 mild and 8 severe) with RSV infection. We tested RNA from blood samples using next-generation sequencing to profile global mRNA expression and identify cellular processes. Results: Retractions, decreased breath sounds, and tachypnea were associated with disease severity. We observed upregulation of genes related to neutrophil, inflammatory response, blood coagulation, and downregulation of genes related to T cell response in children with severe RSV. Using network-based approach, 43 drugs were identified that are predicted to interact with the gene products of these differentially expressed genes. Conclusions: These results suggest that the changes in the expression pattern in the innate and adaptive immune responses may be associated with RSV clinical severity. Compounds that target these cellular processes can be repositioned as candidate drugs in the treatment of severe RSV. Impact: Neutrophil, inflammation, and blood coagulation genes are upregulated in children with severe RSV infection.Expression of T cell response genes are suppressed in cases of severe RSV.Genes identified in this study can contribute in understanding the pathogenesis of RSV disease severity.Drugs that target cellular processes associated with severe RSV can be repositioned as potential therapeutic options.
AB - Background: The limited treatment options for children with severe respiratory syncytial virus (RSV) infection highlights the need for a comprehensive understanding of the host cellular response during infection. We aimed to identify host genes that are associated with severe RSV disease and to identify drugs that can be repurposed for the treatment of severe RSV infection. Methods: We examined clinical data and blood samples from 37 hospitalized children (29 mild and 8 severe) with RSV infection. We tested RNA from blood samples using next-generation sequencing to profile global mRNA expression and identify cellular processes. Results: Retractions, decreased breath sounds, and tachypnea were associated with disease severity. We observed upregulation of genes related to neutrophil, inflammatory response, blood coagulation, and downregulation of genes related to T cell response in children with severe RSV. Using network-based approach, 43 drugs were identified that are predicted to interact with the gene products of these differentially expressed genes. Conclusions: These results suggest that the changes in the expression pattern in the innate and adaptive immune responses may be associated with RSV clinical severity. Compounds that target these cellular processes can be repositioned as candidate drugs in the treatment of severe RSV. Impact: Neutrophil, inflammation, and blood coagulation genes are upregulated in children with severe RSV infection.Expression of T cell response genes are suppressed in cases of severe RSV.Genes identified in this study can contribute in understanding the pathogenesis of RSV disease severity.Drugs that target cellular processes associated with severe RSV can be repositioned as potential therapeutic options.
UR - http://www.scopus.com/inward/record.url?scp=85099985184&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099985184&partnerID=8YFLogxK
U2 - 10.1038/s41390-020-01347-9
DO - 10.1038/s41390-020-01347-9
M3 - Article
C2 - 33510411
AN - SCOPUS:85099985184
SN - 0031-3998
VL - 89
SP - 1664
EP - 1672
JO - Pediatric Research
JF - Pediatric Research
IS - 7
ER -